Metabolic Health: Why GLP-1s Were Never the Whole Answer
GLP-1 drugs sparked the metabolic health boom, but the platforms building around it are betting the real product is what happens after the prescription.
MBX 4291 Monthly GLP-1 Shows 7% Weight Loss at Eight Weeks
MBX 4291 hit 7% weight loss at 8 weeks with a 26-day half-life supporting true once-monthly dosing — and Phase 1 data shows no serious safety signals.
Peptide Telehealth in 2026: The GLP-1 Distribution Model Reaches Longevity
LifespanningRx's partner program brings compounded peptide protocols to independent clinicians in 24 hours — the same telehealth model that mainstreamed GLP-1.
EL-22: The Engineered Probiotic Targeting the Muscle Loss That GLP-1 Drugs Leave Behind
NorthStrive Biosciences has patented EL-22, a myostatin-inhibiting probiotic designed to preserve lean muscle during GLP-1-driven weight loss — addressing one of the category's most significant side effects.
Muscle as Medicine: Why Strength Is the Missing Variable in Longevity
When 40% of weight-loss drug results come from muscle, health outcomes worsen. Here's why strength — not scale weight — is the longevity lever that determines outcomes.
VITAL-H: The $38M Trial Testing Rapamycin, Ozempic, and Farxiga Against Aging
A federally funded trial at UT Health San Antonio is testing three FDA-approved drugs in 726 healthy adults aged 60–65 to see if aging itself can be slowed with existing medications.
Peter Attia's AMA 81: Biological Age Tests, GLP-1s, and What Actually Moves the Needle
AMA 81 covers biological age clocks, GLP-1 receptor agonists, Zone 2 training, and sun exposure — a distillation of what biohacking evidence says is worth acting on in 2026.